Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (211-220 of 527) with videos related to

Pageof 53
Sort By:
Antiviral Research|November 26, 2009
Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patientsChia-Yen Dai, Wan-Long Chuang, Ming-Yen Hsieh, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 7, 2019
Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basisJee-Fu Huang, Pei-Chien Tsai, Ming-Lun Yeh, et al.
Hepatology International|November 11, 2010
Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patientsChung-Feng Huang, Ming-Yen Hsieh, Jeng-Fu Yang, et al.
Medicine|July 12, 2016
Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapyChung-Feng Huang, Ming-Lun Yeh, Cing-Yi Huang, et al.
Medicine|March 18, 2008
Heat shock protein A1B 1267 polymorphism is highly associated with risk and prognosis of hepatocellular carcinoma: a case-control studyJen-Eing Jeng, Jung-Fa Tsai, Lea-Yea Chuang, et al.
The Journal of Infectious Diseases|December 3, 2005
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infectionChia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
Hepatology International|July 24, 2015
The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter studyChung-Feng Huang, Jee-Fu Huang, Wu-Cheng Chen, et al.
Hepatology (Baltimore, Md.)|October 24, 2006
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapyMing-Lung Yu, Shi-Ming Lin, Chuan-Mo Lee, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 18, 2003
Clinical significance of TT virus (TTV) infection in chronic hepatitis C patients with high dose interferon-alpha therapy in Taiwan: re-evaluated by using new set of TTV primersChia Yen Dai, Ming Lung Yu, Zu Yau Lin, et al.
The Kaohsiung Journal of Medical Sciences|November 5, 2020
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatmentTzu-Sheng Cheng, Po-Cheng Liang, Chung-Feng Huang, et al.
Pageof 53

Showing results (211-220 of 527) with videos related to

Sort By:
Pageof 53
Antiviral Research|November 26, 2009
Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patientsChia-Yen Dai, Wan-Long Chuang, Ming-Yen Hsieh, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 7, 2019
Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basisJee-Fu Huang, Pei-Chien Tsai, Ming-Lun Yeh, et al.
Hepatology International|November 11, 2010
Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patientsChung-Feng Huang, Ming-Yen Hsieh, Jeng-Fu Yang, et al.
Medicine|July 12, 2016
Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapyChung-Feng Huang, Ming-Lun Yeh, Cing-Yi Huang, et al.
Medicine|March 18, 2008
Heat shock protein A1B 1267 polymorphism is highly associated with risk and prognosis of hepatocellular carcinoma: a case-control studyJen-Eing Jeng, Jung-Fa Tsai, Lea-Yea Chuang, et al.
The Journal of Infectious Diseases|December 3, 2005
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infectionChia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
Hepatology International|July 24, 2015
The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter studyChung-Feng Huang, Jee-Fu Huang, Wu-Cheng Chen, et al.
Hepatology (Baltimore, Md.)|October 24, 2006
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapyMing-Lung Yu, Shi-Ming Lin, Chuan-Mo Lee, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 18, 2003
Clinical significance of TT virus (TTV) infection in chronic hepatitis C patients with high dose interferon-alpha therapy in Taiwan: re-evaluated by using new set of TTV primersChia Yen Dai, Ming Lung Yu, Zu Yau Lin, et al.
The Kaohsiung Journal of Medical Sciences|November 5, 2020
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatmentTzu-Sheng Cheng, Po-Cheng Liang, Chung-Feng Huang, et al.
Pageof 53